Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, ...

Experts express concern that last week's unprecedented FDA layoffs will trigger a little-known mechanism that could result in a "disaster" the Trump administration doesn't see coming.

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with ...

As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug ...